Balchem (NASDAQ:BCPC) Price Target Raised to $170.00

Balchem (NASDAQ:BCPC) had its price objective hoisted by HC Wainwright from $167.00 to $170.00 in a research note released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Balchem’s Q2 2025 earnings at $1.04 EPS and Q4 2025 earnings at $1.12 EPS.

Separately, StockNews.com lowered Balchem from a buy rating to a hold rating in a research note on Thursday, April 25th.

Balchem Price Performance

Balchem stock opened at $153.28 on Monday. The business’s 50-day simple moving average is $150.98 and its 200 day simple moving average is $141.30. The stock has a market cap of $4.97 billion, a price-to-earnings ratio of 43.30, a P/E/G ratio of 3.33 and a beta of 0.72. Balchem has a 12-month low of $110.74 and a 12-month high of $159.52. The company has a quick ratio of 1.72, a current ratio of 2.61 and a debt-to-equity ratio of 0.31.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The business had revenue of $228.70 million for the quarter, compared to analysts’ expectations of $234.66 million. During the same quarter last year, the business earned $0.66 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, research analysts anticipate that Balchem will post 4.1 earnings per share for the current year.

Insider Buying and Selling at Balchem

In other news, CAO William A. Backus sold 9,180 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the sale, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at $2,019,362.18. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CAO William A. Backus sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total transaction of $2,320,950.00. Following the sale, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at $1,998,183.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO William A. Backus sold 9,180 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total value of $1,435,476.60. Following the sale, the chief accounting officer now directly owns 12,914 shares in the company, valued at approximately $2,019,362.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,630 shares of company stock valued at $11,843,249. 1.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Balchem

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC boosted its position in Balchem by 0.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 14,532 shares of the basic materials company’s stock worth $1,803,000 after acquiring an additional 104 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Balchem by 5.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,935 shares of the basic materials company’s stock valued at $984,000 after buying an additional 386 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Balchem by 6.3% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 25,684 shares of the basic materials company’s stock valued at $3,186,000 after buying an additional 1,515 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Balchem by 16.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,661 shares of the basic materials company’s stock valued at $826,000 after buying an additional 931 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Balchem by 1.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,244 shares of the basic materials company’s stock valued at $1,767,000 after buying an additional 180 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.